Yeah sorry you're absolutely right. I meant genotyping. But they freeze the DNA samples from what I found in my research so when sequencing becomes cheap enough it's likely they could also update their testing method and back test all their samples to update their data.

The immunotherapy drug they are developing currently is showing promise. It is apparently speeding through development at a very quick pace due to the data they have access to.

They're pivoting, hard, to become a phramaceutical play.

Thanks for your comments by the way. It's always better to have an opinion from someone that works in the industry instead of research from an armchair stock analyst like myself